Clinical Trial Detail

NCT ID NCT02499120
Title Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer
Indications

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

Therapies

Palbociclib

Cetuximab

Age Groups: adult

No variant requirements are available.